Phaseline

Targets › FGA

FGA (Fibrinogen alpha chain [Cleaved into: Fibrinopeptide A; Fibrinogen alpha chain]): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 3; Hematology, Other; next expected readout Dec 2026.

Cleaved by the protease thrombin to yield monomers which, together with fibrinogen beta (FGB) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function in hemostasis as one of the primary components of blood clots. (UniProt, P02671)

Open in Phaseline: the race on FGA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Corza MedicalFibrinogen, Human
Fibrinogen exogenous protein
FGA, FGB, FGGPhase 3HemorrhageDec 2026
CSL BehringCSL511 Fibrinogen concentrate (human)
Fibrinogen (clotting factor I) replacement
FGAPhase 3Acquired Fibrinogen DeficiencyJun 2027

Conditions

Acquired Fibrinogen Deficiency (1) Hemorrhage (1)

Modalities

protein or peptide (1), mixed (1)

Companies

CSL Behring (1) Corza Medical (1)

Related targets

FGB (1) FGG (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.